Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus nivolumab versus nivolumab in advanced hepatocellular carcinoma after tyrosine kinase inhibitor progression
2018-003151-38Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Sep 2020; status: active.
02
Drugs
relatlimabnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-003151-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003151-38.